{"hands_on_practices": [{"introduction": "The interpretation of diagnostic tests is a cornerstone of modern medicine. While sensitivity and specificity are intrinsic properties of a test, its real-world utility is defined by its predictive values. This first exercise [@problem_id:4658783] provides a foundational application of Bayes' theorem to calculate the Positive Predictive Value ($PPV$) and Negative Predictive Value ($NPV$) for the CT halo sign, a classic radiological finding in Invasive Aspergillosis ($IA$). Mastering this calculation is the first step toward making evidence-based diagnostic judgments.", "problem": "A cohort of immunocompromised adults with prolonged neutropenia in a hematologic malignancy ward is undergoing chest Computed Tomography (CT) to assess for invasive aspergillosis (IA). The CT halo sign is treated as a binary diagnostic test for IA. In this population, assume the following are well-established from prior studies: sensitivity $Se = 0.80$, specificity $Sp = 0.60$, and the point prevalence of IA (the prior probability of disease) $p = P(D) = 0.25$, where $D$ denotes the event that a patient truly has IA. Let $T+$ and $T-$ denote a positive and negative CT halo sign, respectively. Using the foundational definitions of sensitivity and specificity, the law of total probability, and Bayes’ theorem, derive the expressions for the positive predictive value $PPV = P(D \\mid T+)$ and the negative predictive value $NPV = P(\\overline{D} \\mid T-)$ in terms of $Se$, $Sp$, and $p$, and then evaluate these expressions numerically for the given values. Express both $PPV$ and $NPV$ as decimals (do not use the percentage symbol), and round your final numerical answers to four significant figures. Report your final numerical answers in the order $PPV$, $NPV$.", "solution": "The problem is first validated against the required criteria.\n\n### Step 1: Extract Givens\n- Sensitivity of the CT halo sign: $Se = P(T+ \\mid D) = 0.80$\n- Specificity of the CT halo sign: $Sp = P(T- \\mid \\overline{D}) = 0.60$\n- Prevalence (prior probability) of invasive aspergillosis (IA): $p = P(D) = 0.25$\n- Event $D$: A patient has IA.\n- Event $\\overline{D}$: A patient does not have IA.\n- Event $T+$: A positive test result (CT halo sign is present).\n- Event $T-$: A negative test result (CT halo sign is absent).\n- Required quantities:\n  1.  Positive Predictive Value, $PPV = P(D \\mid T+)$\n  2.  Negative Predictive Value, $NPV = P(\\overline{D} \\mid T-)$\n\n### Step 2: Validate Using Extracted Givens\nThe problem is scientifically grounded, well-posed, and objective. It presents a standard application of Bayesian probability theory to medical diagnostics, a common practice in epidemiology and clinical medicine. The terms (sensitivity, specificity, prevalence, PPV, NPV) are standard and well-defined. The provided values are plausible for a diagnostic test in a high-risk population. The problem is self-contained, with all necessary information provided to derive the required expressions and compute the numerical values. There are no contradictions, ambiguities, or violations of scientific or mathematical principles.\n\n### Step 3: Verdict and Action\nThe problem is valid. A full solution will be provided.\n\n### Derivation of Positive Predictive Value (PPV)\nThe positive predictive value, $PPV$, is the probability that a patient has the disease given a positive test result, which is expressed as the conditional probability $P(D \\mid T+)$. Using the definition of conditional probability (which is a rearrangement of the definition of joint probability), we have:\n$$PPV = P(D \\mid T+) = \\frac{P(D \\cap T+)}{P(T+)}$$\nThis is the core of Bayes' theorem.\n\nThe numerator, $P(D \\cap T+)$, is the joint probability of having the disease and testing positive. It can be expressed using the definition of sensitivity, $Se = P(T+ \\mid D) = \\frac{P(D \\cap T+)}{P(D)}$. Rearranging this gives:\n$$P(D \\cap T+) = P(T+ \\mid D) \\times P(D) = Se \\times p$$\nThe denominator, $P(T+)$, is the overall probability of a positive test. We can expand this using the law of total probability, by conditioning on the disease status (either the patient has the disease, $D$, or does not, $\\overline{D}$):\n$$P(T+) = P(T+ \\mid D)P(D) + P(T+ \\mid \\overline{D})P(\\overline{D})$$\nWe identify the terms:\n- $P(T+ \\mid D) = Se$ (Sensitivity)\n- $P(D) = p$ (Prevalence)\n- $P(\\overline{D}) = 1 - P(D) = 1 - p$\n- $P(T+ \\mid \\overline{D})$ is the probability of a positive test in a patient without the disease (the false positive rate). It is related to specificity, $Sp = P(T- \\mid \\overline{D})$, which is the probability of a negative test in a patient without the disease. Since a test is either positive or negative, $P(T+ \\mid \\overline{D}) + P(T- \\mid \\overline{D}) = 1$. Therefore, $P(T+ \\mid \\overline{D}) = 1 - Sp$.\n\nSubstituting these into the expression for $P(T+)$:\n$$P(T+) = (Se \\times p) + ((1 - Sp) \\times (1 - p))$$\nCombining the numerator and denominator, we derive the expression for $PPV$ in terms of $Se$, $Sp$, and $p$:\n$$PPV = \\frac{Se \\times p}{(Se \\times p) + ((1 - Sp) \\times (1 - p))}$$\n\n### Derivation of Negative Predictive Value (NPV)\nThe negative predictive value, $NPV$, is the probability that a patient does not have the disease given a negative test result, or $P(\\overline{D} \\mid T-)$. Using the definition of conditional probability:\n$$NPV = P(\\overline{D} \\mid T-) = \\frac{P(\\overline{D} \\cap T-)}{P(T-)}$$\nThe numerator, $P(\\overline{D} \\cap T-)$, is the joint probability of not having the disease and testing negative. It can be expressed using the definition of specificity, $Sp = P(T- \\mid \\overline{D}) = \\frac{P(\\overline{D} \\cap T-)}{P(\\overline{D})}$. Rearranging gives:\n$$P(\\overline{D} \\cap T-) = P(T- \\mid \\overline{D}) \\times P(\\overline{D}) = Sp \\times (1 - p)$$\nThe denominator, $P(T-)$, is the overall probability of a negative test. Using the law of total probability:\n$$P(T-) = P(T- \\mid D)P(D) + P(T- \\mid \\overline{D})P(\\overline{D})$$\nWe identify the terms:\n- $P(D) = p$\n- $P(\\overline{D}) = 1 - p$\n- $P(T- \\mid \\overline{D}) = Sp$ (Specificity)\n- $P(T- \\mid D)$ is the probability of a negative test in a patient with the disease (the false negative rate). It is related to sensitivity, $Se = P(T+ \\mid D)$. Since $P(T+ \\mid D) + P(T- \\mid D) = 1$, we have $P(T- \\mid D) = 1 - Se$.\n\nSubstituting these into the expression for $P(T-)$:\n$$P(T-) = ((1 - Se) \\times p) + (Sp \\times (1 - p))$$\nCombining the numerator and denominator, we derive the expression for $NPV$ in terms of $Se$, $Sp$, and $p$:\n$$NPV = \\frac{Sp \\times (1 - p)}{(Sp \\times (1 - p)) + ((1 - Se) \\times p)}$$\n\n### Numerical Evaluation\nWe are given the values $Se = 0.80$, $Sp = 0.60$, and $p = 0.25$.\nFirst, we calculate the complementary probabilities:\n- $1 - p = 1 - 0.25 = 0.75$\n- $1 - Se = 1 - 0.80 = 0.20$\n- $1 - Sp = 1 - 0.60 = 0.40$\n\nNow, substitute these values into the derived expressions.\n\nFor $PPV$:\n$$PPV = \\frac{0.80 \\times 0.25}{(0.80 \\times 0.25) + (0.40 \\times 0.75)} = \\frac{0.20}{0.20 + 0.30} = \\frac{0.20}{0.50} = 0.40$$\nRounding to four significant figures gives $0.4000$.\n\nFor $NPV$:\n$$NPV = \\frac{0.60 \\times 0.75}{(0.60 \\times 0.75) + (0.20 \\times 0.25)} = \\frac{0.45}{0.45 + 0.05} = \\frac{0.45}{0.50} = 0.90$$\nRounding to four significant figures gives $0.9000$.\n\nThe positive predictive value is $0.4000$, and the negative predictive value is $0.9000$.", "answer": "$$\\boxed{\\begin{pmatrix} 0.4000  0.9000 \\end{pmatrix}}$$", "id": "4658783"}, {"introduction": "Building upon the foundational calculations of predictive values, we now explore one of the most critical concepts in diagnostic reasoning: the influence of pre-test probability. A common pitfall is to assume a \"good\" test is always useful, but its reliability is highly context-dependent. This practice [@problem_id:4658780] illustrates this principle by tasking you to compute the $PPV$ of a single assay across three different patient populations with varying prevalence of $IA$. The results will powerfully demonstrate why clinicians must be astute epidemiologists at the bedside.", "problem": "A clinician is evaluating the performance of a non-culture diagnostic assay for invasive aspergillosis in different patient populations. The assay has sensitivity $0.75$ and specificity $0.90$, based on validation studies in immunocompromised hosts. Consider three plausible clinical settings with true disease prevalence $0.05$, $0.20$, and $0.50$ (for example, general Intensive Care Unit (ICU), high-risk hematology ward, and profoundly neutropenic patients with compatible imaging, respectively). Starting from Bayes' theorem and the core definitions of sensitivity, specificity, and prevalence, derive the expression for the Positive Predictive Value (PPV) and compute the PPV for the three prevalences. Round each PPV to four significant figures. Express each PPV as a unitless decimal and report the three results as a single row matrix using the LaTeX $\\mathrm{pmatrix}$ environment. Then, based on your computations, briefly interpret how shifts in prevalence affect the reliability of a positive test in guiding initiation of mold-active antifungal therapy in invasive aspergillosis.", "solution": "## PROBLEM VALIDATION\n\n### Step 1: Extract Givens\nThe problem statement provides the following information:\n-   Assay sensitivity, $Se = 0.75$\n-   Assay specificity, $Sp = 0.90$\n-   Prevalence $1$, $p_1 = 0.05$\n-   Prevalence $2$, $p_2 = 0.20$\n-   Prevalence $3$, $p_3 = 0.50$\n-   The task is to derive the expression for the Positive Predictive Value (PPV) from first principles (Bayes' theorem, definitions of sensitivity, specificity, prevalence).\n-   The task is to compute the PPV for the three given prevalences.\n-   The computed PPV values must be rounded to four significant figures.\n-   The three results must be reported as a single row matrix.\n-   The task is to interpret how prevalence affects the reliability of a positive test.\n\n### Step 2: Validate Using Extracted Givens\nThe problem is subjected to validation against the specified criteria.\n-   **Scientifically Grounded:** The problem is a standard and fundamental application of Bayesian probability to the interpretation of medical diagnostic tests. The context, invasive aspergillosis, is a real and significant infectious disease. The provided values for sensitivity, specificity, and prevalence are clinically plausible for a non-culture-based assay in the described patient populations. The problem is firmly rooted in epidemiology and biostatistics.\n-   **Well-Posed:** All necessary data ($Se$, $Sp$, and a set of prevalences) are provided. The objective—to derive the PPV formula, calculate its value for specific inputs, and interpret the results—is clear and leads to a unique, stable solution.\n-   **Objective:** The problem is stated in precise, quantitative, and unbiased language. It does not contain subjective claims or opinions.\n\nThe problem does not exhibit any of the listed flaws:\n1.  **Scientific or Factual Unsoundness:** None. The premises are consistent with established principles of probability theory and medical diagnostics.\n2.  **Non-Formalizable or Irrelevant:** None. The problem is a direct and formalizable application of mathematical principles to its stated topic, invasive aspergillosis.\n3.  **Incomplete or Contradictory Setup:** None. The setup is self-contained and consistent.\n4.  **Unrealistic or Infeasible:** None. The numerical values are realistic for a real-world clinical scenario.\n5.  **Ill-Posed or Poorly Structured:** None. The question leads to a single, well-defined set of answers.\n6.  **Pseudo-Profound, Trivial, or Tautological:** None. While a standard exercise, the problem requires a formal derivation and calculation, illustrating a critical concept in evidence-based medicine that is far from trivial.\n7.  **Outside Scientific Verifiability:** None. The derivation and calculations are mathematically verifiable.\n\n### Step 3: Verdict and Action\nThe problem is **valid**. The solution process will now proceed.\n\n## SOLUTION\n\nWe are tasked with deriving the Positive Predictive Value (PPV) and calculating it for three different disease prevalences. Let us define the relevant events:\n-   $D$: The event that a patient has the disease (invasive aspergillosis).\n-   $D^c$: The event that a patient does not have the disease.\n-   $T^+$: The event that the diagnostic assay returns a positive result.\n-   $T^-$: The event that the diagnostic assay returns a negative result.\n\nThe given quantities can be expressed in terms of conditional probabilities:\n-   Prevalence ($p$): The prior probability of having the disease, $P(D) = p$. Consequently, the probability of not having the disease is $P(D^c) = 1 - P(D) = 1 - p$.\n-   Sensitivity ($Se$): The probability of a positive test given the patient has the disease, $Se = P(T^+ | D)$. We are given $Se = 0.75$.\n-   Specificity ($Sp$): The probability of a negative test given the patient does not have the disease, $Sp = P(T^- | D^c)$. We are given $Sp = 0.90$.\n\nThe Positive Predictive Value (PPV) is defined as the probability that a patient has the disease given that they have received a positive test result. In probabilistic terms, $PPV = P(D | T^+)$.\n\nWe start from Bayes' theorem to derive the expression for PPV:\n$$PPV = P(D | T^+) = \\frac{P(T^+ | D) P(D)}{P(T^+)}$$\nThe numerator contains terms that are already defined: $P(T^+ | D) = Se$ and $P(D) = p$.\n\nThe denominator, $P(T^+)$, represents the total probability of obtaining a positive test result. This can be calculated using the law of total probability, by marginalizing over the disease status (present or absent):\n$$P(T^+) = P(T^+ | D) P(D) + P(T^+ | D^c) P(D^c)$$\nLet's analyze the terms in this expression:\n-   $P(T^+ | D) = Se$ (Sensitivity)\n-   $P(D) = p$ (Prevalence)\n-   $P(D^c) = 1 - p$\n-   $P(T^+ | D^c)$ is the probability of a positive test in a disease-free individual, also known as the false positive rate. It is related to the specificity, $Sp$. Since for a disease-free individual, the test can only be positive or negative, we have $P(T^+ | D^c) + P(T^- | D^c) = 1$. Therefore, the false positive rate is $P(T^+ | D^c) = 1 - P(T^- | D^c) = 1 - Sp$.\n\nSubstituting these into the expression for $P(T^+)$:\n$$P(T^+) = (Se)(p) + (1 - Sp)(1 - p)$$\nNow, we substitute this complete expression for the denominator back into the Bayes' theorem formula for PPV:\n$$PPV(p, Se, Sp) = \\frac{P(T^+ | D) P(D)}{P(T^+ | D) P(D) + P(T^+ | D^c) P(D^c)} = \\frac{(Se)(p)}{(Se)(p) + (1 - Sp)(1 - p)}$$\nThis is the derived expression for PPV in terms of prevalence ($p$), sensitivity ($Se$), and specificity ($Sp$).\n\nNext, we compute the PPV for the three given prevalences using the provided values: $Se = 0.75$ and $Sp = 0.90$. The term $(1 - Sp)$ is the false positive rate, which is $1 - 0.90 = 0.10$.\n\nThe specific formula for this problem is:\n$$PPV(p) = \\frac{0.75 \\cdot p}{0.75 \\cdot p + 0.10 \\cdot (1 - p)}$$\n\n**Case 1: Prevalence $p_1 = 0.05$**\n$$PPV_1 = \\frac{0.75 \\cdot 0.05}{0.75 \\cdot 0.05 + 0.10 \\cdot (1 - 0.05)} = \\frac{0.0375}{0.0375 + 0.10 \\cdot 0.95} = \\frac{0.0375}{0.0375 + 0.095} = \\frac{0.0375}{0.1325} \\approx 0.2830188...$$\nRounding to four significant figures, $PPV_1 = 0.2830$.\n\n**Case 2: Prevalence $p_2 = 0.20$**\n$$PPV_2 = \\frac{0.75 \\cdot 0.20}{0.75 \\cdot 0.20 + 0.10 \\cdot (1 - 0.20)} = \\frac{0.15}{0.15 + 0.10 \\cdot 0.80} = \\frac{0.15}{0.15 + 0.08} = \\frac{0.15}{0.23} \\approx 0.6521739...$$\nRounding to four significant figures, $PPV_2 = 0.6522$.\n\n**Case 3: Prevalence $p_3 = 0.50$**\n$$PPV_3 = \\frac{0.75 \\cdot 0.50}{0.75 \\cdot 0.50 + 0.10 \\cdot (1 - 0.50)} = \\frac{0.375}{0.375 + 0.10 \\cdot 0.50} = \\frac{0.375}{0.375 + 0.05} = \\frac{0.375}{0.425} \\approx 0.8823529...$$\nRounding to four significant figures, $PPV_3 = 0.8824$.\n\nThe three PPV values are $0.2830$, $0.6522$, and $0.8824$.\n\n**Interpretation:**\nThe computations clearly demonstrate that the Positive Predictive Value (PPV) is highly dependent on the pre-test probability, or prevalence, of the disease in the population being tested.\n-   In the low-prevalence setting ($p=0.05$, e.g., a general ICU), a positive test has a PPV of only $0.2830$. This means that over $70\\%$ of positive results are false positives. Initiating potent, potentially toxic, and costly mold-active antifungal therapy based solely on this result would be a poor clinical decision, as it is more likely to be wrong than right.\n-   In the moderate-prevalence setting ($p=0.20$, e.g., a high-risk hematology ward), the PPV rises to $0.6522$. A positive test now indicates a $65.22\\%$ chance of true disease, making the test substantially more reliable in guiding the decision to treat.\n-   In the high-prevalence setting ($p=0.50$, e.g., a profoundly neutropenic patient with corresponding radiological findings), the pre-test probability is already high. The assay's positive result yields a PPV of $0.8824$, indicating a very high post-test probability of disease. In this context, the test provides strong confirmatory evidence, and initiating therapy is a very reasonable action.\n\nIn conclusion, the clinical utility of this diagnostic assay for invasive aspergillosis is not an intrinsic property of the test alone but is critically modulated by the clinical context, which determines the pre-test probability. The same test can range from being misleading in a low-risk population to being highly informative and clinically actionable in a high-risk population. This underscores the core principle of evidence-based medicine: diagnostic tests should be interpreted in the context of the patient's prior probability of disease.", "answer": "$$\n\\boxed{\n\\begin{pmatrix}\n0.2830  0.6522  0.8824\n\\end{pmatrix}\n}\n$$", "id": "4658780"}, {"introduction": "Clinical decision-making rarely hinges on a single test result; it requires a synthesis of all available evidence to weigh potential benefits against harms. This capstone exercise [@problem_id:4658775] moves from interpreting a single test to evaluating and comparing entire clinical strategies. Using the formal framework of decision analysis, you will model the complex trade-offs between an empirical versus a diagnostics-guided antifungal approach, integrating probabilities, treatment effects, toxicities, and patient-centered outcomes (Quality-Adjusted Life Years, or $QALYs$). This practice simulates the high-level quantitative reasoning required to develop sound clinical policies.", "problem": "A high-risk cohort of adults with acute myeloid leukemia and prolonged neutropenia presents with persistent fever on day $4$ despite broad-spectrum antibacterial therapy. You must compare two day-$4$ antifungal strategies aimed at preventing morbidity and mortality from Invasive Aspergillosis (IA): (i) immediate empirical mold-active antifungal therapy for all patients, and (ii) diagnostics-guided therapy using noninvasive imaging and serum biomarkers, namely chest Computed Tomography (CT) and serum Galactomannan (GM), with antifungal therapy initiated only if the composite test is positive. Use a one-year decision-analytic horizon with Quality-Adjusted Life Year (QALY) as the utility. All uncertainties are independent unless noted. Every patient receives concurrent antibacterial therapy.\n\nFundamental inputs are as follows:\n- Pretest probability of IA at day $4$: $p_{\\mathrm{IA}} = 0.18$.\n- Composite diagnostics-guided testing (chest CT plus serum GM, positive if either is positive): sensitivity $= 0.80$, specificity $= 0.88$.\n- If a patient truly has IA and receives early antifungal therapy at day $4$, the one-year mortality is $0.30$; if antifungal therapy is withheld at day $4$ (missed IA), the one-year mortality is $0.65$.\n- If a patient does not have IA, the one-year mortality is $0.05$ irrespective of antifungal exposure.\n- Among one-year survivors, QALYs accrue as follows: survivors without IA have $0.60$ QALY, survivors with IA treated early have $0.50$ QALY, and survivors with IA whose therapy is withheld at day $4$ have $0.45$ QALY.\n- Mold-active antifungal exposure carries a probability $0.12$ of clinically significant toxicity that causes a QALY decrement of $0.03$ over the one-year horizon. For the purposes of this model, apply this decrement in expectation to all patients who receive antifungal therapy, independent of survival.\n- Toxicity does not change mortality in this model.\n- In the empirical strategy, all patients receive antifungal therapy at day $4$. In the diagnostics-guided strategy, only patients with a positive composite test receive antifungal therapy at day $4$.\n\nTasks:\n- Construct a decision tree with branches for IA versus no IA, test outcomes under the diagnostics-guided strategy (true positive, false negative, true negative, false positive), and clinical outcomes (survival or death) with the above QALY assignments. Clearly state all branch probabilities implied by the inputs.\n- Compute the expected QALYs per patient for each strategy by taking the probability-weighted sum of branch utilities, subtracting the expected QALY decrement from antifungal toxicity among those treated.\n- Let $E_{\\mathrm{emp}}$ be the expected QALYs for empirical therapy and $E_{\\mathrm{dx}}$ for diagnostics-guided therapy. Compute the incremental expected utility $\\Delta = E_{\\mathrm{emp}} - E_{\\mathrm{dx}}$.\n\nReport a single number: the value of $\\Delta$ rounded to four significant figures. Express the final result in Quality-Adjusted Life Years (QALYs).", "solution": "We start from the definitions of sensitivity, specificity, and expected utility. Sensitivity is the probability that the test is positive given disease, and specificity is the probability that the test is negative given no disease. The expected utility is the sum over all disjoint outcome branches of the product of branch probability and branch utility. We apply the law of total probability to partition by IA status and test result where appropriate.\n\nDefine the following symbols:\n- $p_{\\mathrm{IA}} = 0.18$, and $p_{\\neg \\mathrm{IA}} = 1 - p_{\\mathrm{IA}} = 0.82$.\n- Test sensitivity $Se = 0.80$, specificity $Sp = 0.88$.\n- IA treated early mortality $m_{T} = 0.30$, survival $s_{T} = 1 - m_{T} = 0.70$.\n- IA untreated mortality $m_{U} = 0.65$, survival $s_{U} = 1 - m_{U} = 0.35$.\n- No IA mortality $m_{N} = 0.05$, survival $s_{N} = 1 - m_{N} = 0.95$.\n- Survivor QALYs: no IA $Q_{N} = 0.60$, IA treated $Q_{T} = 0.50$, IA untreated $Q_{U} = 0.45$.\n- Antifungal toxicity probability $p_{\\mathrm{tox}} = 0.12$, decrement $\\Delta Q = 0.03$.\n- Expected QALY decrement per treated patient from toxicity: $D = p_{\\mathrm{tox}} \\times \\Delta Q = 0.12 \\times 0.03 = 0.0036$.\n\nStrategy $1$ (empirical therapy):\n- All patients receive antifungal therapy at day $4$, so the fraction treated is $1$ and the expected toxicity decrement applied to the cohort is $1 \\times D = 0.0036$.\n- Expected QALYs are computed as the sum of IA and non-IA contributions to survival-weighted QALYs, minus the toxicity decrement:\n$$\nE_{\\mathrm{emp}} = p_{\\mathrm{IA}} \\times \\left(s_{T} \\times Q_{T}\\right) + p_{\\neg \\mathrm{IA}} \\times \\left(s_{N} \\times Q_{N}\\right) - 1 \\times D.\n$$\nCompute the survival-weighted QALYs:\n$$\ns_{T} \\times Q_{T} = 0.70 \\times 0.50 = 0.35,\\quad s_{N} \\times Q_{N} = 0.95 \\times 0.60 = 0.57.\n$$\nTherefore,\n$$\nE_{\\mathrm{emp}} = 0.18 \\times 0.35 + 0.82 \\times 0.57 - 0.0036.\n$$\nCompute:\n$$\n0.18 \\times 0.35 = 0.063,\\quad 0.82 \\times 0.57 = 0.4674,\n$$\nso\n$$\nE_{\\mathrm{emp}} = 0.063 + 0.4674 - 0.0036 = 0.5268.\n$$\n\nStrategy $2$ (diagnostics-guided therapy):\n- Among IA patients, a fraction $Se = 0.80$ is treated early, and a fraction $1 - Se = 0.20$ is not treated at day $4$.\n- Among non-IA patients, a fraction $1 - Sp = 0.12$ is falsely positive and treated, while a fraction $Sp = 0.88$ is not treated.\n- The fraction of the entire cohort treated under diagnostics-guided therapy is\n$$\np_{\\mathrm{treated,dx}} = p_{\\mathrm{IA}} \\times Se + p_{\\neg \\mathrm{IA}} \\times (1 - Sp) = 0.18 \\times 0.80 + 0.82 \\times 0.12.\n$$\nCompute this:\n$$\n0.18 \\times 0.80 = 0.144,\\quad 0.82 \\times 0.12 = 0.0984,\\quad p_{\\mathrm{treated,dx}} = 0.2424.\n$$\n- Expected QALYs within the IA stratum are a mixture of treated and untreated IA outcomes:\n$$\nE_{\\mathrm{IA}|\\mathrm{dx}} = Se \\times (s_{T} \\times Q_{T}) + (1 - Se) \\times (s_{U} \\times Q_{U}).\n$$\nCompute $s_{U} \\times Q_{U}$:\n$$\ns_{U} \\times Q_{U} = 0.35 \\times 0.45 = 0.1575.\n$$\nThus,\n$$\nE_{\\mathrm{IA}|\\mathrm{dx}} = 0.80 \\times 0.35 + 0.20 \\times 0.1575 = 0.28 + 0.0315 = 0.3115.\n$$\nWeighted by $p_{\\mathrm{IA}}$, the IA contribution to expected QALYs is\n$$\np_{\\mathrm{IA}} \\times E_{\\mathrm{IA}|\\mathrm{dx}} = 0.18 \\times 0.3115 = 0.05607.\n$$\n- In the non-IA stratum, survival and QALY are independent of antifungal exposure in this model, so the contribution is simply\n$$\np_{\\neg \\mathrm{IA}} \\times (s_{N} \\times Q_{N}) = 0.82 \\times 0.57 = 0.4674.\n$$\n- Subtract the expected toxicity decrement applied only to those treated:\n$$\n\\text{Toxicity decrement} = p_{\\mathrm{treated,dx}} \\times D = 0.2424 \\times 0.0036 = 0.00087264.\n$$\nTherefore, the diagnostics-guided expected QALYs are\n$$\nE_{\\mathrm{dx}} = 0.05607 + 0.4674 - 0.00087264 = 0.52259736.\n$$\n\nIncremental expected utility:\n$$\n\\Delta = E_{\\mathrm{emp}} - E_{\\mathrm{dx}} = 0.5268 - 0.52259736 = 0.00420264.\n$$\n\nRounding to four significant figures yields\n$$\n\\Delta \\approx 0.004203\\ \\text{QALYs}.\n$$\nBy sign, $\\Delta > 0$, so empirical therapy has the higher expected QALYs under the stated assumptions. The requested single reported value is $\\Delta$ in QALYs rounded to four significant figures.", "answer": "$$\\boxed{0.004203}$$", "id": "4658775"}]}